Hormonal treatment of hepatocellular carcinoma.

[1]  F. Farinati,et al.  Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. , 1990, Journal of hepatology.

[2]  B. Levin,et al.  A phase II trial of tamoxifen in hepatocellular carcinoma , 1990, Cancer.

[3]  G. Passalacqua,et al.  [Hepatocellular carcinoma (HCC): the long-term response to tamoxifen. A clinical case report and review of the literature]. , 1989, Minerva medica.

[4]  J. Korula,et al.  Failure of ketoconazole as anti-androgen therapy in nonresectable primary hepatocellular carcinoma. , 1988, Journal of clinical gastroenterology.

[5]  P. Johnson,et al.  Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. , 1987, Cancer treatment reports.

[6]  A. Forbes,et al.  Response to cyproterone acetate treatment in primary hepatocellular carcinoma is related to fall in free 5 alpha-dihydrotestosterone. , 1987, European journal of cancer & clinical oncology.

[7]  J. Trinchet,et al.  [Treatment of 25 patients with hepatocellular carcinoma with an anti-androgen, cyproterone acetate (Androcur)]. , 1987, Gastroentérologie Clinique et Biologique.

[8]  M. Lynch,et al.  Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitizes them to the anti-proliferative effects of tamoxifen. , 1987, British Journal of Cancer.

[9]  J. Trinchet,et al.  [Effects of a tamoxifen-norethisterone combination in 16 patients with hepatocellular carcinoma]. , 1985, Gastroentérologie Clinique et Biologique.

[10]  P. Paliard,et al.  [Treatment of hepatocellular carcinoma with tamoxifen]. , 1984, Gastroentérologie Clinique et Biologique.

[11]  D. Demanes,et al.  Hepatomas: hormone receptors and therapy. , 1982, The American journal of medicine.